VIA Pharmaceuticals is a biotechnology company focused on the treatment of cardiovascular disease.

VIA is building a pipeline of small-molecule drugs that target a significant unmet medical need – reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke.

The company’s lead drug candidate, VIA-2291, is in multiple Phase 2 clinical trials in patients with cardiovascular disease to provide clinical proof-of-concept as early as possible in the clinical development process. The innovative Phase 2 trial designs utilize a combination of measures such as biomarkers, non-invasive medical imaging of the coronary vessel and various plaque bioassays.

VIA’s development pipeline also includes additional pre-clinical small molecule drugs that target various stages of vascular inflammation.